Indeed, in validation drug-response assays, Elesclomol strongly decreased viability of EwS cells with high SOX6 levels while the osteosarcoma cell line SAOS-2 and non-transformed human primary MSC line MSC-52 that exhibit low SOX6 expression levels were relatively resistant (Fig. 4c, d). This evidence concerns the gene SOX6 and osteosarcoma.